中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2010年
11期
18-19
,共2页
原发性肝癌%TACE%PVE%HIFU%疗效评价%生存率
原髮性肝癌%TACE%PVE%HIFU%療效評價%生存率
원발성간암%TACE%PVE%HIFU%료효평개%생존솔
Hepatocellular carcinoma%TACE%PVE%HIFU%Efficacy evaluation%Survival rate
目的 研究TACE.PVE.HIFU序贯治疗原发性肝癌临床疗效及方法.方法 将我院60例原发性肝癌患者随机分为两组:治疗组30例:TACE.PVE.HIFU序贯治疗;对照组30例:给予经导管化疗栓塞术(TACE).两组患者治疗后对其临床疗效进行评价分析,所有患者随访3年观察生存情况,并分析相关因素.结果 60例原发性肝癌患者,治疗组总有效率为16例占53.3%,而对照组7例占23.3%,治疗组治疗后临床疗效明显要好于对照组.两组原发性肝癌患者治疗后,其治疗组3年生存率为14例占46.7%,而对照组8例占26.7%,治疗组生存率明显高与对照组.60例原发性肝癌不同肝功能Child分级患者治疗后:6个月生存率51例占85.0%、1年生存率43例占71.7%、2年生存率32例占53.3%、3年生存率22例占36.7%.肝功能Child A生存率较高.结论 TACE.PVE.HIFU序贯治疗在原发性肝癌应用互为补充,最终达到彻底杀灭癌细胞的目的.
目的 研究TACE.PVE.HIFU序貫治療原髮性肝癌臨床療效及方法.方法 將我院60例原髮性肝癌患者隨機分為兩組:治療組30例:TACE.PVE.HIFU序貫治療;對照組30例:給予經導管化療栓塞術(TACE).兩組患者治療後對其臨床療效進行評價分析,所有患者隨訪3年觀察生存情況,併分析相關因素.結果 60例原髮性肝癌患者,治療組總有效率為16例佔53.3%,而對照組7例佔23.3%,治療組治療後臨床療效明顯要好于對照組.兩組原髮性肝癌患者治療後,其治療組3年生存率為14例佔46.7%,而對照組8例佔26.7%,治療組生存率明顯高與對照組.60例原髮性肝癌不同肝功能Child分級患者治療後:6箇月生存率51例佔85.0%、1年生存率43例佔71.7%、2年生存率32例佔53.3%、3年生存率22例佔36.7%.肝功能Child A生存率較高.結論 TACE.PVE.HIFU序貫治療在原髮性肝癌應用互為補充,最終達到徹底殺滅癌細胞的目的.
목적 연구TACE.PVE.HIFU서관치료원발성간암림상료효급방법.방법 장아원60례원발성간암환자수궤분위량조:치료조30례:TACE.PVE.HIFU서관치료;대조조30례:급여경도관화료전새술(TACE).량조환자치료후대기림상료효진행평개분석,소유환자수방3년관찰생존정황,병분석상관인소.결과 60례원발성간암환자,치료조총유효솔위16례점53.3%,이대조조7례점23.3%,치료조치료후림상료효명현요호우대조조.량조원발성간암환자치료후,기치료조3년생존솔위14례점46.7%,이대조조8례점26.7%,치료조생존솔명현고여대조조.60례원발성간암불동간공능Child분급환자치료후:6개월생존솔51례점85.0%、1년생존솔43례점71.7%、2년생존솔32례점53.3%、3년생존솔22례점36.7%.간공능Child A생존솔교고.결론 TACE.PVE.HIFU서관치료재원발성간암응용호위보충,최종체도철저살멸암세포적목적.
Objective To study TACE. PVE. HIFU clinical efficacy of sequential treatment of primary liver cancer and methods. Methods 60 patients with primary liver cancer in our hospital were randomly divided into two groups: treatment group 30: TACE. PVE. HIFU sequential therapy; control group, 30 cases: give transcatheter chemoembolization ( TACE ). After treatment, to evaluate the clinical efficacy analysis, all patients were followed up for 3 years observation of survival, and analysis of relevant factors. Results 60 patients with primary liver cancer, total effective rate was 53.3% in 16 cases, 7 cases of the control group, 23.3% clinical efficacy in treatment group significantly better than the control group. Two groups of patients with primary liver cancer, its treatment of 3-year survival rate was 46. 7% for the 14 cases, while 8 patients accounted for 26. 7%, significantly higher survival rate in treatment group and control group. 60 cases of primary liver cancer patients with different grades of liver function after treatment Child: 6-month survival rate of 85.0% in 51 cases, 43 patients 1 year survival rate of 71.7% , 2-year survival rate of 32 cases of 53.3% , 3 years 36. 7% survival rate of 22 cases. Child A liver function have a higher survival rate. Conclusion TACE. PVE. HIFU sequential treatment of primary liver cancer in the application should complement each other to complete the purpose of killing cancer cells.
